Mereo BioPharma Group plc Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Mereo BioPharma Group plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • Mereo BioPharma Group plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$7.83M, a 22.6% increase year-over-year.
  • Mereo BioPharma Group plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2024 was -$34.8M.
  • Mereo BioPharma Group plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$25.3M, a 52.2% increase from 2022.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$34.8M -$7.83M +$2.28M +22.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$37.1M -$12.3M -$11.9M -3390% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$25.2M -$9.75M +$49K +0.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$25.3M -$5.01M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$10.1M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$351K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$9.8M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.